Thailand Chromosomal Abnormalities: PGT-A & PGT-SR Conditions & Procedures for Third-Generation IVF
Opening: Direct Answer
Direct Answer: Patients with chromosomal abnormalities can undergo third-generation IVF in Thailand, provided they have confirmed clear medical indications through genetic counseling and choose a fertility center with the technical capability for PGT-A (screening for chromosomal aneuploidy) or PGT-SR (screening for structural chromosomal rearrangements). Thailand has accumulated over a decade of clinical experience in the field of embryo chromosomal screening, but there are certain thresholds regarding applicable boundaries, technical pathways, and procedural details.
===================== H2 1 =====================Types of Chromosomal Abnormalities and Applicable Boundaries for Third-Generation IVF
Chromosomal abnormalities in reproductive medicine are mainly divided into two categories: numerical abnormalities and structural abnormalities. Not all chromosomal abnormalities are suitable for or require resolution through third-generation IVF; judgment must be based on specific karyotype results and clinical background.
Numerical Abnormalities
Refers to an increase or decrease in the number of chromosomes, such as Trisomy 21, Trisomy 18, Trisomy 13, Turner Syndrome (45,X), Klinefelter Syndrome (47,XXY), etc. If one partner is a carrier of a numerical chromosomal abnormality (e.g., mosaicism), or if there has been a previous pregnancy with an aneuploid fetus, PGT-A can screen for embryos with a normal number of chromosomes for transfer.
Structural Abnormalities
Includes balanced translocation, Robertsonian translocation, inversion, deletion, duplication, etc. Among these, carriers of balanced translocation and Robertsonian translocation account for approximately 0.2% to 0.5% of the population, and these patients have a significantly increased rate of spontaneous miscarriage. PGT-SR technology can identify whether an embryo carries an unbalanced structural rearrangement, helping to select embryos with normal structure.
Technical Pathways for Third-Generation IVF in Thailand: PGT-A and PGT-SR
Mainstream fertility centers in Thailand primarily use the NGS (Next-Generation Sequencing) platform for embryo chromosomal screening, while some centers retain SNP array or aCGH technology. The distinctions between different technical pathways are as follows:
| Technical Pathway | Scope of Detection | Applicable Scenarios | Biopsy Method |
|---|---|---|---|
| PGT-A | Numerical abnormalities of 24 chromosomes | Advanced maternal age, recurrent miscarriage, risk of aneuploidy | Trophectoderm cell biopsy (Day 5/6) |
| PGT-SR | Structural chromosomal rearrangements (translocation, inversion, etc.) | Carriers of balanced translocation, Robertsonian translocation | Trophectoderm cell biopsy + parental karyotype analysis |
| PGT-M (Monogenic disorders) | Specific gene mutations | Monogenic genetic diseases | Requires combination with PGT-A or separate probe design |
Note: Some centers in Thailand can offer combined PGT-A+SR screening, but this requires additional testing time.
===================== H2 3 =====================Actual Process: From Genetic Counseling to Embryo Transfer
The following is the standard process for patients with chromosomal abnormalities traveling to Thailand for third-generation IVF. The timing of each step should be adjusted based on individual circumstances and the center's schedule.
- Domestic Genetic Counseling and Karyotype Confirmation — Both partners undergo peripheral blood karyotype analysis, with additional FISH or CMA if necessary to clarify the type of abnormality. A genetic counselor assesses suitability for PGT-SR or PGT-A and provides a consultation record.
- Remote Consultation with Thai Fertility Center — Submit previous examination reports (karyotype, AMH, FSH, semen analysis, etc.). The center's genetic advisor reviews the information and determines a preliminary plan.
- Travel to Thailand for Ovarian Stimulation and Egg Retrieval — Stimulation starts on day 2-3 of menstruation, with egg retrieval approximately 10-14 days later. The male partner provides a semen sample during this period.
- Embryo Culture and Biopsy — Blastocysts form by day 5-6 after egg retrieval. After laser-assisted hatching, 3-5 trophectoderm cells are extracted for testing.
- PGT Testing and Result Interpretation — The testing cycle takes about 10-14 days. The result report indicates the chromosomal number and structural status of the embryos, categorized as: euploid (normal), aneuploid (abnormal), or mosaic (some cells abnormal).
- Frozen Embryo Transfer — Select a chromosomally normal euploid embryo for transfer in a subsequent menstrual cycle, using hormone replacement or a natural cycle.
- Post-Transfer Follow-up — Blood β-hCG test 12-14 days after transfer, and ultrasound at 7-8 weeks of gestation to confirm fetal heartbeat.
Doctor's Perspective: Suitable and Unsuitable Populations
From a reproductive medicine perspective, the following classifications can help patients determine if they are suitable for third-generation IVF in Thailand.
Suitable Population
- One or both partners are carriers of balanced chromosomal translocation or Robertsonian translocation, with a natural pregnancy miscarriage rate >70%.
- Previous pregnancy confirmed as chromosomal aneuploidy (e.g., Trisomy 21, Trisomy 18), with an increased risk of recurrence in subsequent pregnancies.
- Female age ≥38 years, with a significantly increased rate of embryonic aneuploidy; PGT-A can reduce the miscarriage rate.
- Unexplained recurrent miscarriage (≥2 times) after excluding uterine, immune, coagulation, and other factors.
- Recurrent IVF implantation failure (≥3 times) with acceptable embryo morphological scores.
Unsuitable Population
- Chromosomal abnormality not yet definitively diagnosed, based only on speculation or reports from non-standard institutions.
- Severely diminished ovarian reserve (AMH <0.5 ng/mL, basal antral follicle count <3), resulting in very few eggs retrieved and a low probability of obtaining biopsiable blastocysts.
- Uncontrolled systemic diseases or severe uterine abnormalities that cannot be improved for the implantation window.
- Seeking PGT solely for sex selection; Thai laws and ethical requirements mandate medical indications.
Differences Between Countries: Thailand vs. Other Regions
Patients choosing Thailand as their destination for third-generation IVF often focus on the following comparative dimensions:
| Dimension | Thailand | USA/Europe | Mainland China |
|---|---|---|---|
| PGT Technical Maturity | Primarily NGS platform, 10-15 years of lab experience | NGS + whole genome sequencing, more advanced frontier research | PGT started later, some centers need to send samples out for testing |
| Applicable Indication Requirements | Strict genetic counseling, but relatively flexible | Requires complete genetic reports and specialist referral | Stricter indication review, must comply with national regulations |
| Cost (One Cycle) | 80,000 – 150,000 RMB (including PGT) | 250,000 – 400,000 RMB | 60,000 – 120,000 RMB (depending on center) |
| Language and Communication | Some centers have Chinese coordinators | Requires translation or English communication | No language barrier in native language |
| Cross-border Convenience | Short distance, simple visa process, short flight time | Requires long-haul flight, longer visa processing time | No need to leave the country |
Thailand strikes a good balance between technical level and cost, but patients should verify the target center's actual PGT case numbers and laboratory quality control data.
===================== H2 6 =====================Easily Overlooked Details
- Management of Mosaic Embryos: Mosaic embryos (20%–50% abnormal cells) in PGT results are not absolutely untransferable; decisions require case-by-case evaluation based on genetic counseling and center policy. Some centers in Thailand are cautious about transferring mosaic embryos; it is advisable to confirm in advance.
- Necessity of Parental Karyotype Analysis: PGT-SR testing requires peripheral blood karyotype data from both partners as a baseline. Some patients only have karyotype data for one partner, making accurate interpretation of results impossible.
- Traceability of Test Results: Different laboratories have varying thresholds for interpreting chromosomal copy number variations. It is recommended to choose a laboratory accredited by CAP or ISO 15189.
- Number of Cells Biopsied from Embryo: Too few biopsied cells may reduce detection rates, while too many may affect embryo viability. In Thailand, 3-5 cells are typically biopsied; confirm the center's standard.
- Completeness of Genetic Counseling Records: Thai fertility centers require complete genetic counseling records and informed consent forms. Missing documents may delay treatment.
Frequently Asked Questions
Q1: What is the success rate of third-generation IVF for chromosomal abnormalities?
The success rate of third-generation IVF primarily depends on whether there are chromosomally normal embryos available for transfer. For carriers of balanced translocation, approximately 20% to 40% of blastocysts per cycle are euploid. If a euploid embryo is obtained, the live birth rate per single transfer is about 40% to 55%, depending on age and embryo quality.
Q2: Which fertility centers in Thailand can perform PGT-SR?
Major fertility centers in Bangkok, such as BNH Hospital, Jetanin Hospital, Bumrungrad Hospital, and EK Hospital, offer PGT services. However, the technical threshold for PGT-SR is higher than for PGT-A. It is recommended to directly ask the center about the number of PGT-SR cycles completed and the abnormality detection rate in the past 1-2 years.
Q3: What materials do patients with chromosomal abnormalities need to prepare for third-generation IVF in Thailand?
You need to provide: ID documents and passports for both partners, complete chromosomal karyotype reports, genetic counseling records, history of previous pregnancies and miscarriages, female AMH and baseline hormone tests, and male semen analysis. Some centers require infectious disease screening (Hepatitis B, Hepatitis C, HIV, Syphilis) from within the last 3 months.
Q4: Does PGT testing damage the embryo?
Laser-assisted biopsy extracts 3-5 trophectoderm cells. Current data suggests it has a limited impact on the blastocyst's implantation potential. However, the embryo must be cryopreserved after biopsy while awaiting test results before transfer. The loss rate from embryo freezing and thawing is approximately 5% to 10%.
Q5: What if all embryos are abnormal?
This situation occurs in about 30% to 60% of cycles for translocation carriers. Options include: undergoing another ovarian stimulation cycle to accumulate embryos, considering egg or sperm donation, or accepting the risk of an abnormal pregnancy despite preimplantation genetic testing. Transferring aneuploid embryos blindly is not recommended.
===================== H2 8 =====================Special Situation Management
The following situations require individualized plans developed jointly with the genetic team at the Thai fertility center:
- Chromosomal Mosaicism Carriers: The mosaic ratio needs to be confirmed via FISH or CMA to assess the impact on offspring. PGT testing requires additional probe design.
- Y Chromosome Microdeletion: Deletion in the AZF region of the Y chromosome in males. Male offspring may inherit the deletion. This may require PGT-M for sex selection or acceptance of carrying the deletion.
- Nuclear Gene Abnormalities Related to Mitochondrial Diseases: Requires PGT-M combined with PGT-A. Only a few centers in Thailand have the capability to design personalized probes.
- Previous Multiple PGT Cycles with No Euploid Embryos: It is recommended to reassess ovarian function, sperm DNA fragmentation rate, and laboratory quality. Consider changing centers or adjusting the stimulation protocol.
This content is compiled based on general knowledge of the assisted reproductive industry and clinical practice in reproductive medicine in Thailand. It does not constitute personal medical advice. Specific plans should be developed by a licensed physician based on the patient's individual circumstances.
